Caroline's Feed
Dec 3, 2012

Drugmakers step up search for hearing loss medicines

ZURICH/LONDON (Reuters) – When Swiss biotech firm Auris Medical wanted to recruit patients to test its experimental hearing loss drug, it decided to enlist partygoers deafened by firecrackers on New Year’s Eve.

In the weeks leading up to December 31, 2005 it advertised in the subway and on radio stations in Munich and Berlin, urging victims of sudden firecracker-induced hearing loss to turn up at designated clinics for treatment on January 1.

Dec 2, 2012

Analysis: Drugmakers step up search for hearing loss medicines

ZURICH/LONDON (Reuters) – When Swiss biotech firm Auris Medical wanted to recruit patients to test its experimental hearing loss drug, it decided to enlist partygoers deafened by firecrackers on New Year’s Eve.

In the weeks leading up to December 31, 2005 it advertised in the subway and on radio stations in Munich and Berlin, urging victims of sudden firecracker-induced hearing loss to turn up at designated clinics for treatment on January 1.

Nov 26, 2012

UK watchdog fines UBS over trading scandal

ZURICH (Reuters) – UBS was fined 30 million pounds ($48 million) by Britain’s financial watchdog and put under extra scrutiny by its Swiss counterpart over failings that allowed a rogue trader to lose $2.3 billion.

Announcing the fine on Monday, Tracey McDermott, director of enforcement at Britain’s Financial Services Authority (FSA), said the Swiss bank’s risk control systems were “seriously defective.”

Nov 26, 2012

FSA fines UBS over trading scandal

ZURICH (Reuters) – UBS was fined 30 million pounds by Britain’s financial watchdog and put under extra scrutiny by its Swiss counterpart over failings that allowed a rogue trader to lose $2.3 billion (1.4 billion pounds).

Announcing the fine on Monday, Tracey McDermott, director of enforcement at Britain’s Financial Services Authority (FSA), said the Swiss bank’s risk control systems were “seriously defective.”

Nov 16, 2012

Novartis’ vaccines business gets chance to prove itself

ZURICH (Reuters) – The European Medicines Agency has thrown Novartis’ loss-making vaccines business a lifeline by recommending its meningitis B shot for approval, which means the pressure is on to make the product a commercial success.

Novartis paid $5.1 billion to gain full control of U.S. vaccine maker Chiron Corp in 2006 in a major bet on vaccines designed to reduce its dependence on prescription drugs ahead of a wave of patent expiries.

Nov 13, 2012

Sonova’s high-tech hearing aids offset price pressures

ZURICH, Nov 13 (Reuters) – Swiss hearing aid maker Sonova’s
focus on new products helped counter margin pressures
in its industry as the group reported stronger first-half
profits on Tuesday, sending its shares to a seven-month high.

Demand from the growing ranks of the elderly has helped
expand the market for hearing aids, but some of Sonova’s
competitors have warned of margin and pricing pressures partly
from cutbacks in government healthcare budgets.

Nov 8, 2012

Novartis says may have 14 new blockbuster drugs by 2017

ZURICH, Nov 8 (Reuters) – Novartis could produce
14 or more new big-selling ‘blockbuster’ drugs within five
years as it bets on cancer, heart and respiratory treatments to
fill the gaps left by expiries on current patents, the Swiss
firm said on Thursday.

Like many of its rivals, Novartis is facing headwinds as
some of its top earners lose patent protection, particularly
blood pressure drug Diovan. It is counting on its newest
products, such as breast cancer drug Afinitor, to pump up sales.

Nov 7, 2012

ABB heralds historic green energy grids game-changer

ZURICH, Nov 7 (Reuters) – Green energy from desert solar
farms or alpine dams can at last be sent across continents
thanks to a breakthrough link device that can cross the great
schism of electricity’s history, ABB said on
Wednesday.

The Swiss engineering group said it had solved a
100-year-old electrical puzzle with its invention of a
high-voltage direct current (HVDC) circuit breaker.

Nov 6, 2012

Adecco sees no early relief for Europe’s job seekers

ZURICH (Reuters) – Adecco (ADEN.VX: Quote, Profile, Research), the world’s biggest staffing group, expects no improvement in Europe’s job markets until late next year because businesses are reluctant to hire due to uncertainty about the euro zone debt crisis.

“It is going to be very slow in Europe into the beginning of next year and if something improves it is going to be in the second half but not before that,” Chief Executive Patrick De Maeseneire told Reuters.

Nov 6, 2012

Adecco sales decline worsens in third-quarter

ZURICH, Nov 6 (Reuters) – Adecco, the world’s
largest temporary staffing firm, said revenues fell further in
Europe in the third quarter, dragged down by the region’s
crippling debt crisis.

Temporary employment is considered a bellwether of broader
labour activity because employers add or cut temps before hiring
and firing permanent staff.